Valtoco Nasal Product
ApprovedSmall molecule
Valtoco Nasal Product is one of 37 small molecule programs targeting Epilepsy. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
221 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Briviact
UCBPhase 3
Dayvigo
EisaiPhase 3
Depacon
AbbViePhase 3
Actemra
RochePhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Narcan
SScienture
Phase 3
GWP42003-P
Jazz PharmaceuticalsPhase 3
Immunoglobulin
SanofiPhase 3
Lamictal
GSKPhase 3
Usual Treatment
UUniversity Hospital, Grenoble
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Epilepsy1 trial
Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care
Active, not recruiting·UUniversity Hospitals Cleveland Medical Center·Approved·NCT06346262·31 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Valtoco Nasal Product. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details